^
Association details:
| Biomarker: | CCDC6-RET fusion |
|---|---|
| Cancer: | Thyroid Gland Anaplastic Carcinoma |
| Drug: | Retevmo (selpercatinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
Published date:
04/16/2020
Excerpt:
This clinically significant response achieved with LOXO-292 in a patient with a CCDC6-RET fusion-positive ATC…
DOI:
10.1089/thy.2019.0477
